Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 15/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | CA4 | P22748 | 3/20 | 0.51 |
| ▸ | CA7 | P43166 | 3/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA3 | P07451 | 2/20 | 0.51 |
| ▸ | CA6 | P23280 | 2/20 | 0.51 |
| ▸ | CA5A | P35218 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.51 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.51 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6248342 | 0.88 | PTGS2 (0.77) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL5698365 | 0.88 | PTGS2 (0.77) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL6736023 | 0.83 | PTGS2 (0.50) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL6726476 | 0.82 | PTGS2 (0.49) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL4888365 | 0.80 | PTGS2 (0.78) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL6728715 | 0.78 | PTGS2 (0.45) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL22827969 | 0.75 | PTGS2 (1.00) | PTGS2PTGS1ESR1ESR2 | |
| SCHEMBL4800056 | 0.75 | PTGS2 (1.00) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL14163959 | 0.75 | PTGS2 (1.00) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL14267668 | 0.75 | PTGS2 (1.00) | PTGS2PTGS1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050131028-A1 | Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders | PHARMACIA CORPORATION (US) | 2005-06-16 | — | — | US | claimed |
| WO-2005025510-A2 | COX-2 SELECTIVE INHIBITOR WITH EXTENDED DURATION | PHARMACIA CORPORATION (US) | 2005-03-24 | — | — | WO | claimed |
| US-20050131028-A1 | Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders | PHARMACIA CORPORATION (US) | 2005-06-16 | — | — | US | disclosed |
| WO-2005025510-A2 | COX-2 SELECTIVE INHIBITOR WITH EXTENDED DURATION | PHARMACIA CORPORATION (US) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131028-A1 | Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders | PTGS2, PTGES2, CNR2 | PTGS2 1/4885PTGS1 8/4885CA1 2613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.